Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Free Report) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 14,200 shares, an increase of 6.8% from the March 15th total of 13,300 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 18,300 shares, the short-interest ratio is currently 0.8 days.
Armata Pharmaceuticals Stock Down 21.9 %
Shares of NYSEAMERICAN ARMP opened at $2.50 on Thursday. The stock has a market capitalization of $90.38 million, a price-to-earnings ratio of -1.26 and a beta of 0.85. Armata Pharmaceuticals has a 1 year low of $1.07 and a 1 year high of $5.26.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.55) earnings per share (EPS) for the quarter. The firm had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.68 million. Armata Pharmaceuticals had a negative return on equity of 280.95% and a negative net margin of 1,524.51%. On average, sell-side analysts predict that Armata Pharmaceuticals will post -1.34 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Stock Report on Armata Pharmaceuticals
Institutional Trading of Armata Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp bought a new stake in shares of Armata Pharmaceuticals during the first quarter valued at approximately $95,000. Jane Street Group LLC bought a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $25,000. HRT Financial LP bought a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $52,000. Renaissance Technologies LLC raised its stake in shares of Armata Pharmaceuticals by 5.6% during the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock valued at $91,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Armata Pharmaceuticals by 51.9% during the third quarter. Vanguard Group Inc. now owns 90,969 shares of the company’s stock valued at $273,000 after acquiring an additional 31,079 shares in the last quarter. Institutional investors own 3.57% of the company’s stock.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Read More
- Five stocks we like better than Armata Pharmaceuticals
- Dividend Payout Ratio Calculator
- United Airlines Soars on Earnings Beat
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Small Caps With Big Return Potential
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.